Heron Therapeutics Inc. (NASDAQ:HRTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Wednesday.

According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “

A number of other research analysts have also recently issued reports on the company. Jefferies Group reissued a “buy” rating and issued a $46.00 target price on shares of Heron Therapeutics in a research note on Wednesday, July 27th. Brean Capital reissued a “buy” rating and issued a $55.00 target price on shares of Heron Therapeutics in a research note on Saturday, August 13th. Cantor Fitzgerald reissued a “buy” rating and issued a $41.00 target price on shares of Heron Therapeutics in a research note on Wednesday, August 3rd. Leerink Swann reissued an “outperform” rating and issued a $33.00 target price on shares of Heron Therapeutics in a research note on Thursday, August 18th. Finally, Lake Street Capital reissued a “buy” rating and issued a $45.00 target price on shares of Heron Therapeutics in a research note on Tuesday, September 6th. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $42.14.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) opened at 17.03 on Wednesday. Heron Therapeutics has a 12-month low of $15.13 and a 12-month high of $31.32. The firm has a 50-day moving average price of $18.73 and a 200-day moving average price of $18.90.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21. Equities analysts forecast that Heron Therapeutics will post ($4.39) earnings per share for the current year.

In related news, insider Robert Rosen sold 100,000 shares of the stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the completion of the transaction, the insider now directly owns 102,640 shares of the company’s stock, valued at $2,391,512. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 20.31% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nationwide Fund Advisors boosted its position in shares of Heron Therapeutics by 10.2% in the second quarter. Nationwide Fund Advisors now owns 20,730 shares of the biotechnology company’s stock valued at $374,000 after buying an additional 1,920 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock valued at $302,000 after buying an additional 1,283 shares during the period. DIAM Co. Ltd. boosted its position in shares of Heron Therapeutics by 7.7% in the second quarter. DIAM Co. Ltd. now owns 300,337 shares of the biotechnology company’s stock valued at $5,406,000 after buying an additional 21,473 shares during the period. Emerald Acquisition Ltd. bought a new position in shares of Heron Therapeutics during the second quarter valued at approximately $451,000. Finally, Swiss National Bank boosted its position in shares of Heron Therapeutics by 3.0% in the second quarter. Swiss National Bank now owns 51,900 shares of the biotechnology company’s stock valued at $937,000 after buying an additional 1,500 shares during the period.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.